Skip to content

Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health

Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01094080
Acronym
BEMIM
Enrollment
505
Registered
2010-03-26
Start date
2010-02-28
Completion date
2018-05-31
Last updated
2020-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Nutrition

Keywords

fully formula fed, fully breast fed

Brief summary

In this study, the suitability of an infant formula with a modified content of protein and fatty acid pattern (LC-PUFA) for healthy term infants will be investigated. Primary hypothesis to be tested is: an infant formula with a modified protein content is non inferior compared to a standard infant formula in respect to the growth of healthy term infants.

Interventions

infants are fed a commercial formula

the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added

OTHERbreast milk

infants are breast fed

Sponsors

HiPP GmbH & Co. Vertrieb KG
CollaboratorINDUSTRY
Ludwig-Maximilians - University of Munich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Days to 28 Days
Healthy volunteers
Yes

Inclusion criteria

* healthy term newborn * gestational age between 37 and 41 weeks * birth weight between the 3th and 97th weight-for-age percentile according to the EURO-Growth charts * fully bottle-fed (at the latest with 28 days of age) or fully breast fed * written parental informed consent * Serbian nationality

Exclusion criteria

* malformations, congenital heart defect, congenital vascular disease, severe diseases of gastrointestinal tract, kidney, liver, central nervous system and/or metabolic disease * intensive care during first 14 days of life * participation in any other clinical study intervention * twins, multiple birth * neonatal infection * medication and parenteral nutrition * metabolic disorders * birth-related complications * severe disturbances of neonatal adaption

Design outcomes

Primary

MeasureTime frame
change of weight from day 30 to day 120postnatal age 30 to 120 days

Secondary

MeasureTime frameDescription
blood markerspostnatal day 30, day 60, day 90, day 120 days (120 only)
anthropometrypostnatal day 30, day 60, day 90, day 120 daysincluding body length, head circumference and derived parameter e.g. weight (from primary outcome) for length
Follow-up4 Years of ageAt 4 Years of Age, an Interview Regarding Severe Events and Growth Since Study End Will be Performed and Anthropometric Data (Weight, Length, Head Circumference and Body Composition Measured Via Skinfolds and BIA) Will be Collected.
Follow-up at age 7 years with an interview regarding severe events and growth7 years of ageAt 7 years of age we will perform anthropometric measurements (weight, height, head circumference and skinfolds) and bioimpedance measurement (from skinfolds and bioimpedance body composition will be estimated) additionally in an interview information on severe events (i.e. diseases) will be collected

Countries

Germany, Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026